文献速递前列腺癌

一种新型可穿戴热疗设备用于管理前列腺癌患者困扰性潮热的可行性

Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-12-13

这项单臂前瞻性研究纳入57例前列腺癌生存者,让其按需使用一种向腕内侧施加冷却的腕戴式热疗设备4周。主要结局为设备使用时长与每日使用次数,并评估潮热相关日常干扰量表(HFRDIS)及PROMIS睡眠 disturb 4a(SD)与睡眠相关损害8a(SRI)评分变化。结果显示设备使用可行,HFRDIS、PROMIS SD与PROMIS SRI自基线至第4周均有统计学显著改善(均p<0.001),未报告不良事件;作者认为结果支持该设备用于管理困扰性潮热的可行性,并认为未来需开展随机对照研究。

要点

  • 57例入组、44例完成研究、39例有可提取使用数据;设备日均使用3.2±2.5小时、每日7.6±3.6次。
  • 第4周HFRDIS较基线平均变化-1.1±0.3,PROMIS SD为-6.0±1.0,PROMIS SRI为-5.5±1.2(均p<0.001)。
  • 69%的参与者报告该热疗设备有助于管理潮热,研究期间未报告不良事件。

核心结论

  • 作者认为结果支持该热疗设备用于管理前列腺癌生存者困扰性潮热的可行性,并认为未来需开展随机对照研究评估其对潮热频率与严重程度、睡眠质量、疲乏及总体生活质量的影响。

研究设计与样本

  • 单臂前瞻性研究,57例入组并指导按需使用腕戴式热疗设备4周;研究流程于2021年5月至12月在美国远程进行。
  • 主要结局为热疗设备使用情况(每日小时数与使用次数);其他结局包括HFRDIS(范围0-10)、PROMIS SD T评分(范围0-100)与PROMIS SRI T评分(范围0-100)的变化。
  • 44例完成研究,39例有可提取的使用数据;平均±SD年龄67±6岁,距癌症诊断5±5年。

主要发现

  • 基线HFRDIS平均±SD评分为4.3±2.0,提示该人群存在中度潮热干扰。
  • 研究期间参与者平均±SD每日使用热疗设备3.2±2.5小时、每日7.6±3.6次。
  • 67%的参与者报告每周7天和7夜使用该设备。
  • 第4周HFRDIS(平均±SE变化:-1.1±0.3)、PROMIS SD(-6.0±1.0)与PROMIS SRI(-5.5±1.2)评分较基线均有统计学显著改善(均p<0.001)。
  • 69%的参与者报告该热疗设备有助于管理潮热;未报告不良事件。

关键数值与推荐

  • HFRDIS评分范围0-10,PROMIS SD T评分范围0-100,PROMIS SRI T评分范围0-100。
  • 第4周HFRDIS平均±SE变化为-1.1±0.3,PROMIS SD为-6.0±1.0,PROMIS SRI为-5.5±1.2(均p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出未来需开展随机对照研究以评估该热疗设备对潮热频率与严重程度、睡眠质量、疲乏及总体生活质量的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This single-arm prospective study evaluated the feasibility of a novel wrist-worn thermal device that applies cooling to the inside of the wrist for management of bothersome hot flashes in prostate cancer survivors. METHODS: 57 individuals were enrolled and instructed to use the thermal device as needed for management of hot flashes for 4 weeks. The primary outcome was thermal device usage (hours and sessions per day). Additional outcomes included the change in Hot Flash Related Daily Interference Scale (HFRDIS, range 0-10) and Patient Reported Outcomes Measurement Information System Sleep Disturbance 4a (PROMIS SD T-score, range 0-100) and Sleep-Related Impairment 8a (PROMIS SRI T-score, range 0-100). Study procedures were conducted remotely from May to Dec 2021 in the US. RESULTS: 44 participants completed the study and 39 had retrievable usage data. The mean ± SD age was 67 ± 6 years and 5 ± 5 years since cancer diagnosis. The baseline mean ± SD HFRDIS score of 4.3 ± 2.0 indicated moderate hot flash interference in this population. During the study, participants used the thermal device (mean ± SD) 3.2 ± 2.5 hours/day and 7.6 ± 3.6 sessions/day. Most (67%) participants reported using the device 7 days and 7 nights each week. Statistically significant improvements from baseline at Week 4 were observed for HFRDIS (mean ± SE change: -1.1 ± 0.3), PROMIS SD (-6.0 ± 1.0), and PROMIS SRI (-5.5 ± 1.2) scores (all p < 0.001). The majority (69%) of participants reported that the thermal device was effective at helping them manage hot flashes. No adverse events were reported. CONCLUSIONS: Results support the feasibility of using the thermal device for management of bothersome hot flashes in prostate cancer survivors. Future randomized controlled studies are warranted to evaluate the impact of the thermal device on frequency and severity of hot flashes, sleep quality, fatigue, and overall quality of life.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Peeke P, Billes SK, Vetter A, et al. Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 38086919. doi:10.1038/s41391-023-00771-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。